<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04646876</url>
  </required_header>
  <id_info>
    <org_study_id>N-142-2019</org_study_id>
    <nct_id>NCT04646876</nct_id>
  </id_info>
  <brief_title>Mgso4 as Neuroprotective in Post Traumatic Brain Injury</brief_title>
  <official_title>Assessment Role of Mgso4 as Neuroprotective in Post Traumatic Brain Injury</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Osama Mohamed Abdelwahab</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to assess the potential role of magnesium sulphate (MgSo4) as a&#xD;
      neuroprotective agent using the Glasgow outcome scale following moderate and severe traumatic&#xD;
      brain injury.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is Prospective , Comparative , double-blind , placebo-controlled study with&#xD;
      randomization&#xD;
&#xD;
      Patients with post traumatic brain injury either moderate (glasgow coma scale GCS = 9-12) or&#xD;
      severe (GCS = 3-8) admitted in one of the neurosurgical ICU of the following centers; kasr El&#xD;
      Aini Hospitals, Beni- Suef University Hospital or Beni- Suef General Hospital.&#xD;
&#xD;
      Study design and statistical inferences Patients with traumatic brain injury included in the&#xD;
      study will be randomly allocated into one of two equal groups (30 patients each): -&#xD;
&#xD;
      Group (A): will receive MgSo4. Group (B): will receive normal saline as a placebo.&#xD;
&#xD;
      Each patient will receive all other standard management as indicated on individual basis&#xD;
      (e.g. Antiepileptics, brain dehydrating measures, antibiotics, ventilatory support, or&#xD;
      surgical intervention when deemed necessary).&#xD;
&#xD;
      The Glasgow outcome scale (GOS) will be used to categorize the outcome after 2 months as&#xD;
      follows:&#xD;
&#xD;
        1. Death&#xD;
&#xD;
        2. Persistent vegetative state: Minimal responsiveness&#xD;
&#xD;
        3. Severe disability: Conscious but disabled; dependent on others for daily support&#xD;
&#xD;
        4. Moderate disability: Disabled but independent; can work in sheltered setting&#xD;
&#xD;
        5. Good recovery: Resumption of normal life despite minor deficits&#xD;
&#xD;
      For each patient, the following will be recorded:&#xD;
&#xD;
        1. Personal data: name, age, sex, address, tel. No.&#xD;
&#xD;
        2. Mode of trauma: fall from height, road traffic accidents, or isolated head trauma.&#xD;
&#xD;
        3. Neurological assessment on admission using the Glasgow coma score.&#xD;
&#xD;
        4. Associated injuries or neurological deficits.&#xD;
&#xD;
        5. Findings of initial CT brain, as well as follow up scans.&#xD;
&#xD;
        6. Any previous illness.&#xD;
&#xD;
      Administration :&#xD;
&#xD;
      Administration regimen of Mgso4 will be as following:&#xD;
&#xD;
      Initial dose: within 24 hrs of trauma 50 mg / kg / IV infusion over 1 hour. Maintenance dose:&#xD;
      25 mg / kg twice daily for 48 hrs.&#xD;
&#xD;
      In order to avoid Mgso4 toxicity, infusion of the medication (either Mgso4 or placebo) will&#xD;
      be abruptly terminated whenever:&#xD;
&#xD;
        1. Urine output &lt; 0.5 ml / kg / hour over 4 hours&#xD;
&#xD;
        2. Blood urea &gt; 50 mg/ dL .&#xD;
&#xD;
        3. Fall of systolic BP &lt; 90 mm Hg.&#xD;
&#xD;
        4. Respiratory center depression (respiratory rate less than 12 per minute).&#xD;
&#xD;
        5. Cardiac arrhythmia.&#xD;
&#xD;
        6. Loss of deep tendon reflexes.&#xD;
&#xD;
      The third supervisor will be responsible for the safety measures of the study, which will be&#xD;
      evaluated by continuous monitoring of vital signs, arterial blood pressure (systolic,&#xD;
      diastolic), urine output, serum chemistry.&#xD;
&#xD;
      Preparation of the drug:&#xD;
&#xD;
      The medication will be prepared by three assistants other than the researcher, one in each&#xD;
      center where the study will be conducted.&#xD;
&#xD;
      For each patient, a set of bottles will be prepared (initial dose, and 4 maintenance doses).&#xD;
      After preparation, each set of bottles will be labeled using the same code consisting of&#xD;
      letters (A, B, C, D, E, F) and figures (0 to 9). Total number of codes will be 60 which is&#xD;
      the total number of patients allocated (A0, A1, A2,....A9&amp; B0, B1, ......B9&amp; C1,...C9&amp;&#xD;
      D0-D9&amp;E0-E9&amp; F0-F9).&#xD;
&#xD;
      Only the second supervisor will be acquainted with the key of the code, either it is the&#xD;
      studied treatment (Mg So4), or normal saline (placebo). He will be responsible for the random&#xD;
      allocation of the patients, and instructing the assistants to prepare either the treatment or&#xD;
      the placebo, and their subsequent coding. He will not be informed about the results which&#xD;
      will be regularly followed by the first supervisor. The key will be kept hidden from the&#xD;
      researcher who will be responsible for recording the results. The key will be disclosed only&#xD;
      after conclusion of the study and collecting the results in order to operate the statistical&#xD;
      analysis.&#xD;
&#xD;
      Each amp of Mgso4 (0.5 gm / 5ml) will be dissolved in 13.5 ml normal saline (at that&#xD;
      concentration, Mgso4 will remain chemically stable for 3 months in room air). For simplicity,&#xD;
      this will compose a unit and will be labeled as mentioned. So one unit equals 500 mg&#xD;
      dissolved in 13.5 ml normal saline. For each patient, the number of units will be calculated&#xD;
      according to the body weight. For example, the initial dose or the daily dose of 70 kg&#xD;
      patient equals 7 units (70 x 50 = 3500 mg). For this patient, 3 bottles will be prepared on&#xD;
      admission, each bottle will be labeled the same as the units, and each bottle will contain 7&#xD;
      units. The first bottle will be given as the initial dose, and the other two bottles will be&#xD;
      divided to 4 equal doses, and will be given over the next 48 hrs. For placebo, the same will&#xD;
      be done, but only using normal saline. Which is identical to Mgso4 regarding color and&#xD;
      aspect.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 2, 2019</start_date>
  <completion_date type="Actual">June 2, 2020</completion_date>
  <primary_completion_date type="Actual">March 12, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>2 groups, comparative</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
    <masking_description>The researcher did not know the type of medication given to the patients, placebo or treatment actually Only investigator knew the key</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Glasgow outcome scale after 2 months</measure>
    <time_frame>60 days from drug administration</time_frame>
    <description>assessment of conscious level of the patients after 60 days of drug administration&#xD;
The Glasgow outcome scale (GOS) has been used to categorize the outcome after 2 months as follows:&#xD;
Death.&#xD;
Persistent vegetative state: Minimal responsiveness.&#xD;
Severe disability: Conscious but disabled; dependent on others for daily support.&#xD;
Moderate disability: Disabled but independent; can work in sheltered setting.&#xD;
Good recovery: Resumption of normal life despite minor deficits.&#xD;
Better score means that the patient conscious level is improved</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Magnesium Sulphate</condition>
  <condition>Traumatic Brain Injury</condition>
  <condition>Brain</condition>
  <condition>Injury</condition>
  <arm_group>
    <arm_group_label>intervention arm ( Group A )</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>including 30 patients Group A was given magnesium Sulphate&#xD;
Administration regimen of Mgso4 was as following:&#xD;
Initial dose: within 24 hrs of trauma 50 mg / kg / IV infusion over 1 hour. Maintenance dose: (25 mg / kg) per dose twice daily for 48 hrs.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo arm (Group B )</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>including 30 patients Placebo control study Group B was given saline as a placebo. with the same regimen and route of administration of magnesium sulphate</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Magnesium Sulfate</intervention_name>
    <description>Prospective , comparative , double blind study</description>
    <arm_group_label>intervention arm ( Group A )</arm_group_label>
    <other_name>Mgso4</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Prospective , comparative , double blind study</description>
    <arm_group_label>Placebo arm (Group B )</arm_group_label>
    <other_name>Saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1) Patients with moderate (GCS = 9-12), or severe (GCS = 3-8) traumatic brain injury.&#xD;
&#xD;
             2) Age above 12 years.&#xD;
&#xD;
             3) Consenting for treatment within 24 hours of trauma.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1) Non consenting patients.&#xD;
&#xD;
             2) Persistent hypotension (BP below 90 / 60) in 1st 24 hours despite measures of&#xD;
             resuscitation.&#xD;
&#xD;
             3) Significant multisystem association (e.g. cord injury with spinal shock).&#xD;
&#xD;
             4) Known case of renal failure&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Osama Awahab, professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Faculty Of Medicine , Beni Suef University , Egypt</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Faculty of medicine , Cairo university</name>
      <address>
        <city>Cairo</city>
        <zip>11511</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>February 22, 2020</study_first_submitted>
  <study_first_submitted_qc>November 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 30, 2020</study_first_posted>
  <last_update_submitted>November 20, 2020</last_update_submitted>
  <last_update_submitted_qc>November 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Osama Mohamed Abdelwahab</investigator_full_name>
    <investigator_title>Professor Osama Mohamed Abdelwahab</investigator_title>
  </responsible_party>
  <keyword>Magnesium</keyword>
  <keyword>Sulphate</keyword>
  <keyword>double</keyword>
  <keyword>blinded</keyword>
  <keyword>randomized</keyword>
  <keyword>control</keyword>
  <keyword>study</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Injuries</mesh_term>
    <mesh_term>Brain Injuries, Traumatic</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Magnesium Sulfate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

